Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer

about

Targeting ALK: Precision Medicine Takes on Drug Resistance.The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer

P2860

Q39103431-F2983B93-56F0-45E8-ADDC-05C5E9773874 Q41396204-633BF705-1D13-4A04-83ED-071ACE0C56C9

P2860

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer

Item

http://www.wikidata.org/entity/Q38880324

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Integration of Stereotactic Bo ...... IV Oncogene-Driven Lung Cancer

@en

type

Item

label

Integration of Stereotactic Bo ...... IV Oncogene-Driven Lung Cancer

@en

prefLabel

Integration of Stereotactic Bo ...... IV Oncogene-Driven Lung Cancer

@en

P1476

Integration of Stereotactic Bo ...... IV Oncogene-Driven Lung Cancer

@en

P2093

Alice T Shaw

http://www.w3.org/2001/XMLSchema#string

Hani Al-Halabi

http://www.w3.org/2001/XMLSchema#string

Henning Willers

http://www.w3.org/2001/XMLSchema#string

Lecia V Sequist

http://www.w3.org/2001/XMLSchema#string

Meghan Campo

http://www.w3.org/2001/XMLSchema#string

Melin Khandekar

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?

Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?

Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

P304

964-973

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2015-0508

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27354669

http://www.w3.org/2001/XMLSchema#string

P932

4978553

http://www.w3.org/2001/XMLSchema#string

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer

about

P2860

P2860

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932